(firstQuint)An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia.

 This is a 26 week, multiregional, open-label extension study designed to evaluate the long-term safety and tolerability of SEP-363856 for the treatment of subjects with schizophrenia who have completed the 4 week double-blind treatment phase of Study SEP361-201.

 No statistical hypothesis tests will be performed.

.

 An Extension Study of Safety and Tolerability of SEP-363856 in Adult Subjects With Schizophrenia@highlight

An extension study of safety and tolerability of SEP-363856 in adult subjects with schizophrenia